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Abstract
Background. Lanthanum carbonate and sevelamer car-
bonate are non-calcium-based phosphate binders used to
manage hyperphosphataemia in patients with chronic kid-
ney disease (CKD). Patients with CKD may require intra-
venous or oral active vitamin D. We investigated the effects
of lanthanum carbonate and sevelamer carbonate on the
bioavailability of oral calcitriol.
Methods. This was a three-period, crossover study in
healthy volunteers. Forty-one individuals were randomized
to one of six possible sequences, each consisting of three
treatment periods separated by washouts. The treatments
were calcitriol (1 μg at lunch), calcitriol with lanthanum
carbonate (3000 mg/day) and calcitriol with sevelamer car-
bonate (7200 mg/day). Serum calcitriol levels were as-
sessed at baseline and throughout the study.
Results. Co-administration of lanthanum carbonate with
calcitriol had no significant effect on area under the curve
over 48 h (AUC0–48) for serum exogenous calcitriol [least-
squares (LS) mean, calcitriol with lanthanum carbonate vs
calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respective-
ly; P = 0.171]. Similarly, there was no significant effect on
maximum concentration (Cmax). In contrast, co-adminis-
tration with sevelamer was associated with a significant re-
duction in bioavailability parameters for calcitriol
(calcitriol with sevelamer carbonate vs calcitriol alone,
LS mean AUC0–48: 137 pg h/mL vs 318 pg h/mL, respect-
ively; P = 0.024; LS mean Cmax: 40.1 pg/mL vs 49.7 pg/
mL, respectively; P < 0.001).
Conclusions. Sevelamer carbonate significantly reduces
serum concentrations of exogenous calcitriol when admi-
nistered concomitantly with oral calcitriol, whereas lan-
thanum carbonate has no significant effect. This should
be considered when treating CKD patients who require
phosphate binders and oral vitamin D.
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Introduction
Vitamin D insufficiency and deficiency are common in pa-
tients with chronic kidney disease (CKD), owing to de-
creased synthesis of 1,25-dihydroxyvitamin D (calcitriol,
the active form of vitamin D) in the kidney [1,2]. A decrease
in 1,25-dihydroxyvitamin D, along with an increase in para-
thyroid hormone, is one of the earliest changes seen in min-
eral metabolism parameters in patients with CKD and this
decrease tends to worsen as CKD progresses [3]. Vitamin
D insufficiency is strongly associated with hyperparathyr-
oidism [4], as well as an increased risk of cardiovascular
events and changes in bone metabolism [5,6]. The Kidney
DiseaseOutcomesQualityInitiativeandtheKidneyDisease:
Improving Global Outcomes guidelines both recommend
that vitamin D insufficiency and deficiency are treated ap-
propriately[7,8].Several preparationsofvitaminD andvita-
min D analogues are available; some are administered orally
and others intravenously. Such agents have been found to be
extremelyeffectiveincontrollinghyperparathyroidisminpa-
tientswithadvancedkidneydisease[9]andinreducingmor-
tality in patients on haemodialysis [10]. Thus, it is important
for nephrologists to be aware of any drug–drug interactions
thatmayimpactontheeffectivenessofvitaminDtreatments.
Phosphate binders are often used to sequester dietary
phosphate in the gastrointestinal tract, thereby reducing
phosphate absorption and helping to manage hyperpho-
sphataemia in patients with CKD. Several binders are cur-
rently available; among these, non-calcium-based
lanthanum carbonate (FOSRENOL
®, Shire Pharmaceuti-
cals, Basingstoke, UK) and sevelamer (Renagel
® and Re-
nvela
®, Genzyme Corporation, Cambridge, MA, USA)
have been shown to be effective in reducing serum phos-
phorus levels in patients with CKD on dialysis [11,12] and
may improve survival, in comparison with calcium-based
binders, in patients over 65 years of age [13,14]. These
non-calcium-based binders have been developed as an al-
ternative to the older calcium-based agents, which may in-
crease the progression of calcification [15].
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volves direct physical binding of phosphate in the contents
of the gastrointestinal tract. In addition to binding phos-
phate, sevelamer has a high affinity for bile salts [16]. In-
deed, it has been shown in vitro that bile salts displace
phosphate from sevelamer, but not from lanthanum [17].
As sevelamer binds bile salts, it may impair the absorption
offat-soluble molecules, such as vitamin D [18]. Sevelamer
hydrochloride has been shown to reduce the bioavailability
of calcitriol in beagle dogs [19], but no specific calcitriol
interaction studies have been reported in humans. Sevela-
mer carbonate is a new formulation of sevelamer, which
may also reduce the absorption of fat-soluble vitamins.
To date, there are no published clinical data in humans
regarding the effect of sevelamer carbonate/hydrochloride
or lanthanum carbonate on the absorption of the vitamin D
supplement, oral calcitriol, which is indicated for patients
with CKD who are vitamin D deficient. In this clinical
pharmacology study, the effects of lanthanum carbonate
and sevelamer carbonate on the pharmacokinetics of oral
calcitriol in healthy volunteers were compared.
Materials and methods
Design
This was an open-label, three-period crossover study comparing the bio-
availability of calcitriol (ROCALTROL
®, Validus Pharmaceuticals, Inc.
Parsippany, NJ, USA) during the following regimens:
￿ calcitriol alone (1 μg at lunch, given as two 0.5 μg capsules)
￿ calcitriol (1 μg at lunch) with lanthanum carbonate (one 1000 mg tablet
at breakfast, lunch and dinner)
￿ calcitriol (1 μg at lunch) with sevelamer carbonate (2400 mg at break-
fast, lunch and dinner, given as three 800 mg tablets).
The dose per day of lanthanum carbonate (3000 mg) was chosen based
on the highest doses usually required in clinical studies; most patients
received 1500–3000 mg/day in order to reach targets [12,20,21]. Data
on the required dosage of sevelamer carbonate are limited; Ketteler et
al. reported a final mean dose of 7800 mg/day in a recent treat-to-target
study [22]. Data on sevelamer hydrochloride suggest a mean dose require-
ment of 5400–6900 mg/day [13,23–26] to achieve control of serum phos-
phate. Thus, we considered a daily dose of sevelamer carbonate of
7200 mg/day to represent a dose within the typical range used in clinical
practice.
Eligible healthy volunteers were admitted to a single study centre
and randomized to one of six treatment sequences (Figure 1), with
each sequence including all three treatment regimens. Treatment peri-
ods each lasted 3 days and were separated from each other by a 7-day
washout. Study treatment was given only on day 1 of each treatment
period. Identical meals were served across the treatment periods and
contained 300–400 mg of phosphorus and 200–300 mg of calcium.
Treatments were administered orally with 240 mL of de-ionized water
half-way through ingestion of the meal. The study was undertaken in
accordance with the Declaration of Helsinki, and all participants provided
written informed consent.
Participants
Eligible healthy volunteers were aged 19–45 years and had a body mass
index of 20.0–29.9 kg/m
2. Women of childbearing potential and sexually
active men were required to use an acceptable method of contraception.
Exclusion criteria included current or recurrent disease that could affect
Fig. 1. Study design. Study medications were administered orally with 240 mL of de-ionized water half-way through ingestion of the meal.
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current or relevant previous history of any medical disorder that might
require treatment or make the subject unlikely to be able to complete
the study; significant illness within 2 weeks of the first dose of study
medication; use of any medication within 2 weeks of the first study dose,
with the exception of hormonal replacement therapy or hormonal contra-
ceptives; a positive test for human immunodeficiency virus antibodies,
hepatitis B surface antigens or hepatitis C antibodies; pregnancy or lac-
tation; smoking or use of nicotine-containing products; a history of alco-
hol abuse, or consumption of more than 21 units/week for men or more
than 14 units/week for women; routine consumption of more than 2 units
of caffeine per day; inability to follow a standardized diet and meal sched-
ule or inability to fast as required during the study; substantial changes in
eating habits in the 30 days before first study dose; and use of any other
investigational agents in the 30 days before first study dose.
Objectives and assessments
The primary objective was to assess the effects of lanthanum carbonate
(1000 mg t.i.d. with meals) and sevelamer carbonate (2400 mg t.i.d. with
meals) on the pharmacokinetics of oral calcitriol (1 μg o.d.). The primary
endpoint was predefined as the change from baseline in area under the
curve over 48 h (AUC0–48) for exogenous calcitriol (i.e. day 1 total calci-
triol minus baseline endogenous calcitriol). Secondary pharmacokinetic
endpoints included maximum concentration (Cmax), AUC until last meas-
urable time point (AUC0–t) and time to maximum concentration (tmax) for
exogenous calcitriol and all the above parameters for total calcitriol.
Blood samples for assessment of serum calcitriol levels were collected
from each participant prior to lunch on the 2 days before study dosing in
each treatment period (days −2 and −1) and at the following time points
after dosing in each treatment period: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36
and 48 h. Serum concentrations of calcitriol were determined by a vali-
dated radioimmunoassay with a working range of 5–210 pg/mL. Samples
from the same individual for different treatment regimens were analysed
in separate batches; however, an incurred sample reproducibility test con-
firmed acceptable inter-batch reproducibility. Serum calcitriol levels in
quality control samples (12.5, 50.0 and 175 pg/mL) analysed alongside
study samples were determined with an accuracy of between −6.5 and
6.9% and a precision (inter-assay coefficient of variation) of between
7.3 and 9.5%. Baseline endogenous serum calcitriol levels were deter-
mined from the mean of values for days −2 and −1. Exogenous serum
calcitriol values at each sampling time following dosing were calculated
from the total serum concentration at that time minus the baseline en-
dogenous serum calcitriol concentration. This method of determining ex-
ogenous calcitriol concentration could result in negative calculated values.
Serum exogenous calcitriol AUC0–48 and AUC0–t were calculated using
individual values for exogenous serum calcitriol levels and could also
have negative values. AUC0–48,A U C 0–t, Cmax and tmax for total calcitriol
were also determined for each treatment.
The secondary objective was to evaluate the safety and tolerability of
lanthanum carbonate and sevelamer carbonate when co-administered with
calcitriol. This was assessed through recording of adverse events and la-
boratory assessments.
Statistical methods
Based on published data, the mean AUC for exogenous serum calcitriol
corresponding to a dose of 1 μg oral calcitriol per day was estimated to be
256 pg h/mL [27]. In this study, an inter-participant coefficient of vari-
ation of 22% was reported for total calcitriol levels (endogenous plus ex-
ogenous). Based on this degree of variability, it was estimated that a total
of 30 participants would allow detection of a 20% reduction in AUC for
serum calcitriol between calcitriol alone and calcitriol with lanthanum
carbonate or sevelamer carbonate, with a two-sided significance level
and 90% power. Assuming that the intra-participant coefficient of vari-
ation (which was not available) would be lower than the inter-participant
variability, sample size was likely to have been overestimated.
The primary hypothesis tested was that there were no differences in the
AUC0–48 for exogenous calcitriol when calcitriol was co-administered
with either lanthanum carbonate (lanthanum carbonate + calcitriol versus
calcitriol alone) or sevelamer carbonate (sevelamer carbonate + calcitriol
versus calcitriol alone). The primary analysis was performed on the phar-
macokinetic population, which consisted of all participants with no major
deviations related to study drug intake for whom the primary pharmaco-
kinetic data were considered sufficient and interpretable. AUC0–48,
AUC0–t and Cmax for exogenous calcitriol were analysed using a mixed-
effect linear model containing sequence group, period and treatment
group as fixed effects and participant-within-sequence as the random ef-
fect. Baseline endogenous calcitriol was included as a covariate. AUC0–48,
AUC0–t and Cmax for total calcitriol were analysed using the same model
as for exogenous calcitriol with the exceptions that the log-transformation
was applied before analyses and baseline serum calcitriol was not in-
cluded in the model. The tmax values for exogenous and total calcitriol
were analysed using Wilcoxon signed-rank sum test.
Results
Volunteer disposition and demographics are shown in
Tables 1 and 2. All 41 participants who were rando-
mized were included in the safety and pharmacokinetic
analyses.
Mean serum concentrations of exogenous and total cal-
citriol after a single dose, with or without co-administra-
tion of lanthanum carbonate or sevelamer carbonate, are
shown in Figure 2. For all regimens, mean exogenous cal-
citriol concentrations rapidly reached a plateau that was
maintained for up to ~6 h, with concentrations then de-
creasing to a calculated level lower than baseline by 48 h
after dosing.
There were no significant changes in exogenous calci-
triol least-squares (LS) mean AUC0–48 or Cmax values
when lanthanum carbonate was co-administered with cal-
citriol, compared with calcitriol alone (Table 3). This was
also the case for total calcitriol. However, median tmax for
exogenous calcitriol and for total calcitriol was longer
when lanthanum carbonate was co-administered with cal-
Table 2. Volunteer demographics (safety population)
Parameter Total (n= 41)
Sex, n (%)
Male 22 (53.7%)
Female 19 (46.3%)
Race, n (%)
White 21 (51.2%)
Black 18 (43.9%)
Asian 2 (4.9%)
Ethnicity, n (%)
Hispanic or Latino 8 (19.5%)
Not Hispanic or Latino 33 (80.5%)
Age, years (mean ± SD) 30 ± 7.6
Weight, kg (mean ± SD) 72 ± 11.0
Body mass index, kg/m
2 (mean ± SD) 24 ± 2.8
Table 1. Volunteer disposition
Population n (%)
Screened 86
Enrolled/randomized 41
Safety population 41 (100.0%)
Pharmacokinetic population 41 (100.0%)
Completed 36 (87.8%)
Discontinued 5
Adverse event 0 (0.0%)
Refused further participation 2 (4.9%)
Withdrew consent 3 (7.3%)
Calcitriol pharmacokinetics: effect of P binders 1617Fig. 2. Mean serum concentrations of (a) exogenous and (b) total calcitriol after a single dose, with or without co-administration of lanthanum
carbonate or sevelamer carbonate. Regimen A: calcitriol 1.0 μg; regimen B: calcitriol 1.0 μg + lanthanum carbonate (1000 mg t.i.d.); regimen C:
calcitriol 1.0 μg + sevelamer carbonate (2400 mg t.i.d.).
Table 3. Analysis of exogenous and total calcitriol pharmacokinetic parameters: lanthanum carbonate plus calcitriol versus calcitriol alone
Exogenous calcitriol
a
Parameter Calcitriol Calcitriol + lanthanum carbonate Difference (95% CI) P-value
AUC0–48 (pg h/mL) 318 429 111 (−49, 270) 0.171
Cmax (pg/mL) 49.7 47.0 −2.7 (−8.1, 2.6) 0.313
tmax (h) 2.0 4.0 1.3 (0.0, 2.5) 0.039
Total calcitriol
b
Parameter Calcitriol Calcitriol + lanthanum carbonate Geometric mean ratio (95% CI) P-value
AUC0–48 (pg h/mL) 2748 2889 1.05 (0.99, 1.12) 0.114
Cmax (pg/mL) 98.6 96.7 0.98 (0.91, 1.05) 0.579
tmax (h) 2.0 4.0 1.3 (0.0, 2.5) 0.039
Note: AUC0–t values were identical to AUC0–48 values. AUC0–48 = area under the serum concentration–time curve from time 0 to 48 h after dosing;
AUC0–t = area under the serum concentration–time curve from time 0 to time (t) of the last quantifiable plasma concentration; Cmax, maximum serum
concentration; tmax, time of maximum serum concentration.
aValues for AUC and Cmax are least-squares mean; median values are given for tmax.
bValues for AUC and Cmax are geometric least-squares mean; median values and median difference are given for tmax.
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alone: 2.0 h; P = 0.039 for both exogenous calcitriol and
total calcitriol) (Table 3).
Co-administration of sevelamer carbonate with calcitriol
resulted in a statistically significant reduction in LS mean
AUC0–48 for serum exogenous calcitriol levels compared
with calcitriol alone {calcitriol with sevelamer carbonate:
137 pg h/mL; calcitriol alone: 318 pg h/mL; difference
[95% confidence interval (95% CI)]: −181 pg h/mL
(−338, −24.0); P = 0.024} (Table 4). Similarly, co-
administration with sevelamer carbonate was associated
with a reduction in LS mean Cmax for exogenous calcitriol
levels (calcitriol with sevelamer carbonate: 40.1 pg/mL;
calcitriol: 49.7 pg/mL; difference [95% CI]: −9.6 [14.9,
−4.34]; P < 0.001) (Table 4). Significant reductions in
LS mean AUC0–48 and Cmax were also observed for total
calcitriol when administered with sevelamer carbonate
compared with calcitriol alone (Table 4).
No serious adverse events were reported and none of the
volunteers withdrew due to an adverse event. In total, 6/38
individuals (15.8%) experienced adverse events during
treatment with calcitriol alone (headache, haematoma, hy-
poaesthesia [two patients], diarrhoea and urinary tract in-
fection). This compares with 10/38 individuals (26.3%)
during treatment with calcitriol and lanthanum carbonate
and 5/40 individuals (12.5%) during treatment with calci-
triol and sevelamer carbonate. The majority of adverse
events were mild or moderate in nature and were not re-
lated to lanthanum carbonate or sevelamer carbonate; only
three events were considered related to treatment, two oc-
curring during treatment with lanthanum carbonate plus
calcitriol (anxiety and headache) and one occurring during
treatment with sevelamer carbonate and calcitriol (dry
mouth). No clinically important changes in laboratory
parameters, physical examinations or electrocardiograms
were detected during the study in any of the treatment
arms.
Discussion
The results of this study demonstrate that, unlike lan-
thanum carbonate, sevelamer carbonate reduces serum
levels of exogenous calcitriol when these agents are
co-administered.
Our study showed that sevelamer carbonate reduced
the systemic exposure to oral calcitriol (measured as
AUC0–48) by ~57%, whereas lanthanum carbonate had
no statistically significant or clinically relevant effect.
Furthermore, Cmax for calcitriol was significantly (19%)
lower when volunteers were co-administered with sevela-
mer carbonate and calcitriol compared with calcitriol
alone. Our results extend to human details contained
within the prescribing information for sevelamer carbon-
ate, which highlight reductions in vitamin D levels in
rats and dogs when given sevelamer hydrochloride and
suggest monitoring for reduced vitamin D [28]. In con-
trast to the results with sevelamer carbonate, lanthanum
carbonate had no significant effect on Cmax. These find-
ings are in line with previous observations by Finn et al.
who showed that lanthanum carbonate does not affect
concentrations of 25-hydroxyvitamin D or 1,25-dihy-
droxyvitamin D (the inactive and active forms of vitamin
D, respectively) in patients with CKD stages 3 and 4
[29].
A direct impact of sevelamer on calcitriol metabolism is
unlikely because absorption of sevelamer is negligible
[30]. However, an indirect interaction (by altering the ab-
sorption of an agent that affected calcitriol metabolism)
cannot be entirely excluded. A more likely explanation
for the reduction in AUC0–48 is that the non-selective bind-
ing properties of sevelamer result in reduced absorption of
both phosphate and calcitriol. Sevelamer consists of a
cross-linked polyallyl skeleton with protonated primary
and secondary amine groups [31]. The hydrocarbon poly-
mer will have affinity for aliphatic polycyclic molecules
(e.g. bile acids, vitamin D, vitamin K) through intermo-
lecular van der Waals attraction [31]. Indeed, sevelamer
has been proven to bind the fat-soluble vitamin K in
vitro, fully sequestering a test sample [32].
Co-administration of calcitriol with lanthanum carbon-
ate resulted in a delay in tmax compared with calcitriol
alone. However, examination of all the concentration–time
curves suggests that a plateau is rapidly reached and
maintained for at least 5 h. For the calcitriol alone regi-
men, the concentration at 2 h was transiently higher but
declined to a plateau consistent with levels seen with
the calcitriol/lanthanum carbonate regimen by the time
of the next sampling point. Given this observation, it is
possible that the apparent difference in tmax (2 h for calci-
Table 4. Analysis of exogenous calcitriol pharmacokinetic parameters: sevelamer carbonate plus calcitriol versus calcitriol alone
Exogenous calcitriol
a
Parameter Calcitriol Calcitriol + sevelamer carbonate Difference (95% CI) P-value
AUC0–48 (pg h/mL) 318 137 −181 (−338, −24) 0.024
Cmax (pg/mL) 49.7 40.1 −9.6 (−14.9, −4.3) <0.001
tmax (h) 2.0 2.5 0.5 (−0.5, 1.5) 0.305
Total calcitriol
b
Parameter Calcitriol Calcitriol + sevelamer carbonate Geometric mean ratio (95% CI) P-value
AUC0–48 (pg h/mL) 2748 2579 0.94 (0.88, 1.00) 0.047
Cmax (pg/mL) 98.6 89.7 0.91 (0.85, 0.98) 0.009
tmax (h) 2.0 2.5 0.5 (−0.5, 1.5) 0.305
Note: AUC0–t values were identical to AUC0–48 values. AUC0–48 = area under the serum concentration–time curve from time 0 to 48 h after dosing;
AUC0–t = area under the serum concentration–time curve from time 0 to time (t) of the last quantifiable plasma concentration; Cmax, maximum serum
concentration; tmax, time of maximum serum concentration.
aValues for AUC and Cmax are least-squares mean; median values are given for tmax.
bValues for AUC and Cmax are geometric least-squares mean; median values and median difference are given for tmax.
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chance finding. Even if there is some reduction in the ab-
sorption rate of calcitriol when given with lanthanum car-
bonate, it is unlikely to have any clinical impact because
systemic exposure is not significantly altered. Results for
total calcitriol were consistent with those for exogenous
calcitriol.
In this study, volunteers received a single dose of calci-
triol alone (1 μg at lunch), a single dose of calcitriol plus
three doses of lanthanum carbonate (1000 mg at breakfast,
lunch and dinner) or a single dose of calcitriol plus three
doses of sevelamer carbonate (2400 mg at breakfast, lunch
and dinner). We acknowledge that the co-administration of
oral calcitriol and phosphate-binding agents in this regi-
men may not be representative of how these treatments
are taken by patients in clinical practice. There are no spe-
cific guidelines regarding when oral calcitriol should be
taken relative to phosphate binders but, for convenience,
patients receiving oral vitamin D supplements and
phosphate binders may take the agents simultaneously
in the absence of guidance concerning any drug–drug
interaction.
An interesting observation in this study is the apparent
fall of serum calcitriol concentrations below baseline levels
for all treatment regimens by 48 h post-dose. The reason
for this phenomenon is unclear. There are data to suggest
that calcitriol administration can induce production of 24-
hydroxylase [33], thus degrading calcitriol and maintain-
ing calcium balance. In theory, this induction could lead
to a reduction in overall calcitriol levels compared with
baseline. However, in a previous pharmacokinetic study
of calcitriol in healthy individuals, calcitriol concentrations
did not return to baseline within a 24-h period [34]. There-
fore, the results in our study cannot be unequivocally at-
tributed to induction of 24-hydroxylase. On examining
the concentration–time curves, it is clear that the standard
deviations about the mean calcitriol concentrations for
baseline and 48-h values overlap. Hence, there is some un-
certainty whether the apparent decline in calcitriol concen-
trations below baseline is real.
Conclusion
Sevelamer carbonate significantly reduces serum concen-
trations of exogenous calcitriol when co-administered with
oral calcitriol in healthy volunteers, whereas lanthanum
carbonate has no clinically relevant effect on exogenous
calcitriol. The most likely explanation for the effect of se-
velamer is a reduction in bioavailability through sequester-
ing the fat-soluble calcitriol. These findings may represent
an important consideration in patients with CKD who
often require vitamin D supplementation.
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